Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review
Mélanie Desaulniers(Université de Sherbrooke), Kim M. Pabst(West German Heart and Vascular Center Essen), Étienne Rousseau(Université de Sherbrooke)
Cited by 12
Related Papers
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145
Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men
|The Journals of Gerontology Series A|2002|91
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
|Journal of Nuclear Medicine|2022|68
Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma
|Journal of Nuclear Medicine|2023|63
Clinical Use of PET/MR in Oncology: An Update
|Seminars in Nuclear Medicine|2021|43